© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 85705 refers to the thromboplastin inhibition test, specifically designed to qualitatively assess the presence of lupus anticoagulants (LA) in a blood specimen. This test is crucial for identifying LA, which are a group of antibodies that can lead to various clinical and laboratory effects. The detection of these antibodies is often incidental, typically revealed when a prolonged activated partial thromboplastin time (APTT) is noted during routine testing. The presence of lupus anticoagulants is frequently associated with autoimmune conditions, particularly systemic lupus erythematosus (SLE), but can also arise from other medical issues such as inflammatory bowel disease, infections, or malignancies. Additionally, certain medications may contribute to the presence of LA. Clinically, lupus anticoagulants can lead to serious complications, including recurrent thromboses, multiple spontaneous miscarriages, migraine headaches, strokes, and bleeding disorders. However, it is important to note that many individuals with LA may remain asymptomatic. The primary purpose of the TTI test is to elucidate the underlying cause of increased clotting times attributed to these antibodies. The testing process involves diluting the blood specimen to enhance sensitivity to the inhibitors present, and the methodology employed can be either photometric or an automated enzyme immunoassay (EIA).
© Copyright 2025 Coding Ahead. All rights reserved.
The thromboplastin inhibition test (CPT® Code 85705) is indicated for the following conditions:
The procedure for conducting the thromboplastin inhibition test involves several key steps to ensure accurate results:
Post-procedure care for patients undergoing the thromboplastin inhibition test is generally minimal, as the test is performed on a blood specimen and does not require any invasive interventions. Patients may resume normal activities immediately following the blood draw. However, it is essential for healthcare providers to communicate the results of the test to the patient, as the presence of lupus anticoagulants may necessitate further evaluation or management strategies to address potential complications associated with increased clotting risks. Follow-up appointments may be scheduled to discuss the implications of the test results and any necessary treatment options.
| Short Descr | THROMBOPLASTIN INHIBITION | Medium Descr | THROMBOPLASTIN INHIBITION TISSUE | Long Descr | Thromboplastin inhibition, tissue | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2005-01-01 | Changed | Code description changed. |
| 1993-01-01 | Added | First appearance in code book in 1993. |
Get instant expert-level medical coding assistance.